Iovance Biotherap…
USUSDIovance Biotherapeutics Inc (US:IOVA) — Biotechnology: Biological Products (No Diagnostic Substances). Nombre de places boursières sur lesquelles les actions de la société sont cotées : 2. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.
À propos de l'entreprise
- Site Web
- iovance.com
- Relations avec les Investisseurs
- ir.iovance.com/
- Secteur
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Siège Social
- San Carlos, United States
- PDG
- Frederick G. Vogt
- Employés
- 975
- Fondée
- 2007
- Actions en Circulation
- 452.97 M au 2026-07-29
- Flottant
- 394.31 M
- Capitalisation Boursière
- 6.71 Md USD
- Initiés
- 0.35%
- Investisseurs Institutionnels
- 70.68%
- Secteur d'Activité (SIC)
- Biological Products, (No Diagnostic Substances)
- ISIN
- US4622601007
- LEI
- 2549002L8WT2ACU5Q878
- P/E
- perte
- FCF
- −296 M USD
- Dette
- 1.00 M USDtrésorerie nette
- Résultats et FCF — pour les 12 mois à 30.06.2026 (dernier rapport de l'entreprise).
- NAV
Description
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Principaux Actionnaires
| Détenteur | Participation | Actions | Date du Rapport |
|---|---|---|---|
| Blackrock Inc. | 8.16% | 36.96 M | 2026-06-30 |
| MHR Fund Management, LLC | 6.39% | 28.97 M | 2026-06-30 |
| State Street Corporation | 5.4% | 24.48 M | 2026-06-30 |
| Two Sigma Investments, L… | 4.2% | 19.01 M | 2026-06-30 |
| Vanguard Capital Managem… | 4.02% | 18.2 M | 2026-06-30 |
| SPDR SERIES TRUST-State… | 3.38% | 15.3 M | 2026-08-31 |
| Vanguard Portfolio Manag… | 3.18% | 14.39 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.98% | 13.49 M | 2026-06-30 |
| Geode Capital Management… | 2.28% | 10.32 M | 2026-06-30 |
| iShares Trust-iShares Ru… | 2.25% | 10.2 M | 2026-08-31 |
| Millennium Management Ll… | 1.88% | 8.53 M | 2026-06-30 |
| Dimensional Fund Advisor… | 1.43% | 6.46 M | 2026-06-30 |
| Palo Alto Investors Lp | 1.17% | 5.3 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.07% | 4.86 M | 2026-06-30 |
| Fidelity Salem Street Tr… | 0.96% | 4.35 M | 2026-07-31 |
| VANGUARD INDEX FUNDS-Van… | 0.95% | 4.31 M | 2026-06-30 |
| iShares Trust-iShares Ru… | 0.82% | 3.71 M | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 0.68% | 3.08 M | 2026-06-30 |
| iShares Trust-iShares Bi… | 0.64% | 2.9 M | 2026-08-31 |
| TIAA-CREF Funds-Nuveen Q… | 0.6% | 2.71 M | 2026-07-31 |
| VOGT FREDERICK G (Chief… | ≈0.13% | 595 447 | 2026-09-08 |
| PURI RAJ K (Officer) | ≈0.06% | 256 364 | 2026-09-08 |
| KIRBY DANIEL GORDON (Off… | ≈0.03% | 154 511 | 2026-08-10 |
| BILINSKY IGOR P (Chief O… | ≈0.03% | 142 074 | 2026-09-08 |
| GRAF FINCKENSTEIN FRIEDR… | ≈0.03% | 140 111 | 2026-06-05 |
| BELLEMIN JEAN-MARC (Chie… | ≈0.01% | 60 529 | 2025-06-02 |
| ROCHE CORLEEN M (Chief F… | ≈0.01% | 28 757 | 2026-08-06 |
| MAYNARD RYAN D (Director… | ≈0% | 7 500 | 2024-11-12 |
